If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCVS Group Regulatory News (CVSG)

Share Price Information for CVS Group (CVSG)

Share Price is delayed by 15 minutes
Get Live Data
1,242.00    -2.00 (-0.16%)
Bid:
1,241.00
Ask:
1,244.00
Spread: 3.00 (0.242%)
Market Cap: £859.46m
CVSG Live PriceLast checked at - London Stock Exchange

Intraday CVS Group Share Chart

Response to CMA Summary Final Decision Report

24 Mar 2026 07:13

RNS Number : 8560X
CVS Group plc
24 March 2026
 

For Immediate Release 24 March 2026

CVS Group plc

("CVS", the "Company" or the "Group")

 

Response to CMA Summary Final Decision Report

 

CVS notes this morning's publication by the Competition and Markets Authority ("CMA") of the summary of its Final Decision Report in the veterinary services market investigation. The CMA is expected to publish its full Final Decision Report later today.

 

CVS welcomes the certainty that this morning's announcement brings after more than two and half years of CMA scrutiny.

 

The CMA's final decision does not introduce any new remedies over and above those announced in its provisional decision. We are pleased to see that the CMA has considered our and the veterinary profession's feedback in amending the proposed fee cap on prescriptions with the cap now increased to £21 inclusive of VAT for the first drug prescribed, with the ability to charge an additional £12.50 for each additional drug prescribed at the same time. Whilst we continue to believe that some of these remedies are not fully justified, we are comfortable with them and believe they are workable. We already comply with many remedies and are well advanced in complying with others, with price lists published on our practice websites in late 2025 and 117 CVS UK companion animal practices already jointly branded.

 

As such, the Board expects the Group to continue to trade in line with market expectations.

 

Whilst the remedies are now certain and will not change, we look forward to discussing the practical implementation of all remedies with the CMA prior to the publication of its Final Order later in 2026 which will bring these remedies into legal effect.

 

Contacts

CVS Group plc via Camarco

Richard Fairman, Chief Executive Officer

Robin Alfonso, Chief Financial Officer

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

 

Camarco (Financial PR)

Ginny Pulbrook cvsg@camarco.co.uk

Tilly Butcher +44 (0)20 3757 4980

Letaba Rimell

 

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

 

The Group operates over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

 

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and 3,300 nurses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RSPPPURUWUPQUMC
Date   Source Headline
13th Dec 20217:00 amRNSPDMR/PCA Dealings
7th Dec 202111:06 amRNSPDMR/PCA Dealings
30th Nov 20217:00 amRNSExercise of Options and Total Voting Rights
26th Nov 20215:31 pmRNSHolding(s) in Company
26th Nov 20215:24 pmRNSHolding(s) in Company
26th Nov 20218:16 amRNSGrant of Options & PDMR Dealing
26th Nov 20217:00 amRNSDirector/PDMR Shareholding
24th Nov 20213:09 pmRNSResult of AGM
24th Nov 20217:00 amRNSAGM Statement and Trading Update
19th Nov 20214:26 pmRNSHolding(s) in Company
10th Nov 202111:17 amRNSHolding(s) in Company
3rd Nov 20212:30 pmRNSPCA Shareholding
1st Nov 20218:00 amRNSHolding(s) in Company
29th Oct 202110:17 amRNSPosting of Annual Report & Notice of AGM
29th Oct 20217:00 amRNSExercise of Options and Total Voting Rights
13th Oct 20216:01 pmRNSExercise of Options, PDMR Dealing and TVR
7th Oct 20211:52 pmRNSHolding(s) in Company
7th Oct 20217:00 amRNSLong Term Incentive Plan Awards & PDMR Dealing
30th Sep 20217:00 amRNSExercise of Options and Total Voting Rights
29th Sep 20215:28 pmRNSHolding(s) in Company
28th Sep 20217:54 amRNSHolding(s) in Company
23rd Sep 20217:00 amRNSBoard Changes
23rd Sep 20217:00 amRNSFinal results for the year ended 30 June 2021
13th Sep 20211:50 pmRNSHolding(s) in Company
31st Aug 20217:00 amRNSExercise of Options and Total Voting Rights
27th Aug 20215:34 pmRNSHolding(s) in Company
26th Aug 20218:48 amRNSBlock Listing Application
24th Aug 20214:10 pmRNSHolding(s) in Company
20th Aug 20212:09 pmRNSHolding(s) in Company
20th Aug 20212:07 pmRNSHolding(s) in Company
30th Jul 202112:00 pmRNSExercise of Options and Total Voting Rights
29th Jul 20214:14 pmRNSHolding(s) in Company
20th Jul 20217:00 amRNSTrading Update
13th Jul 202112:40 pmRNSBlock Listing Interim Review and TVR Update
30th Jun 20217:00 amRNSExercise of Options and Total Voting Rights
28th May 202112:00 pmRNSExercise of Options and Total Voting Rights
13th May 20218:30 amRNSShareholder Consultation regarding 2020 AGM
30th Apr 202112:00 pmRNSExercise of Options and Total Voting Rights
30th Apr 20217:00 amRNSTrading Update
7th Apr 20217:00 amRNSDirector/PDMR Shareholding
31st Mar 20217:00 amRNSExercise of Options and Total Voting Rights
30th Mar 20219:06 amRNSDirector/PDMR and PCA Shareholding
25th Mar 20217:00 amRNSInterim Results
3rd Mar 20217:30 amRNSHolding(s) in Company
26th Feb 202112:00 pmRNSExercise of Options and Total Voting Rights
5th Feb 20214:30 pmRNSHolding(s) in Company
29th Jan 202112:00 pmRNSExercise of Options
29th Jan 20217:00 amRNSTrading Update
6th Jan 20219:30 amRNSBlock Listing Application
5th Jan 20217:00 amRNSLong Term Incentive Plan Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.